GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly
Authors' conclusion
Of 25 patients with acromegaly, 7 had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in 4. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist.
Study context
- Population
- Treatment-naive patients with acromegaly7 with paradoxical growth hormone (GH) secretion
- Participants
- 25 patients
- Comparison
- GIPNH2 infusion vs placebo infusion during oral glucose tolerance test (OGTT)
- Outcome
- Effect of GIP(3-30)NH2 on paradoxical GH secretion during OGTT
Methodological detailsplacebo-controlled, crossover OGTT with placebo and GIP(3-30)NH2 infusion, in vitro and ex vivo confirmation
- Placebo-controlled
- Crossover OGTT with placebo and GIP(3-30)NH2 infusion
- In vitro and ex vivo confirmation
Main finding
As reported in the abstract
Paradoxical GH secretion during OGTT
Paradoxical GH response completely abolished by GIP(3-30)NH2
4 of 7 patients
Further findings
GIP receptor (GIPR) expression in somatotrophs of responders
- Somatotrophs available, all with abundant GIPR expression
- 3 of 4 patients
Adenoma size
- Adenoma size did not differ between patients with and without paradoxical GH secretion
Original publication
GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly. J Clin Endocrinol Metab. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →